Literature DB >> 2789333

Phosphorylation of human interleukin-2 (IL-2).

H F Kung1, I Calvert, E Bekesi, F R Khan, K P Huang, S Oroszlan, L E Henderson, T D Copeland, R C Sowder, S J Wei.   

Abstract

Human interleukin-2 (IL-2) is a lymphokine which is capable of activating lymphocytes and supporting the long-term in vitro growth of activated T cell clones. Recombinant human IL-2, expressed in either E. coli or cos cells, was shown to be phosphorylated by protein kinase C. Phosphorylated IL-2 synthesized in E. coli was analyzed by SDS-PAGE, reverse phase HPLC, and tryptic peptide mapping. The phosphorylated tryptic peptide was identified as the N-terminal fragment containing a single phosphorylation site at the serine residue at position 7. There was no difference in biological activity between non-phosphorylated and phosphorylated IL-2, as determined by a T cell growth assay. Although the physiological role of phosphorylation of IL-2 is unclear, IL-2 can be labeled with [gamma-32P] ATP and protein kinase C to a high specific radioactivity, and the synthesis of biologically active 32p-labeled IL-2 may be useful for receptor-binding studies of the cells containing low level of phosphoprotein phosphotases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789333     DOI: 10.1007/bf00228277

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Heterogeneity of human T-cell growth factor(s) due to variable glycosylation.

Authors:  R J Robb; K A Smith
Journal:  Mol Immunol       Date:  1981-12       Impact factor: 4.407

5.  Molecular characterization of interleukin 2 produced from tumor cell lines and T cell hybridomas.

Authors:  S Gillis; D Mochizuki
Journal:  Curr Top Microbiol Immunol       Date:  1982       Impact factor: 4.291

Review 6.  Studies and perspectives of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

7.  Purification and initial characterization of rat interleukin 2.

Authors:  G Di Sabato
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity.

Authors:  K Welte; C Y Wang; R Mertelsmann; S Venuta; S P Feldman; M A Moore
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

9.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

10.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

View more
  1 in total

Review 1.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.